Maze Therapeutics, Inc. (MAZE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Maze Therapeutics, Inc. (MAZE) closed at USD 26.23 on 2026-10-14, a change of -18.3 % over the past year, with a market capitalization of USD 1.53B.

Maze Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Maze Therapeutics, Inc. key figures

Previous close

USD 26.23 (2026-10-14)

1-year change

-18.3 %

Market cap

USD 1.53B

Enterprise value

USD 1.18B

P/E ratio (trailing)

-11.08

P/E ratio (forward)

-8.52

EPS (trailing)

-2.48

EPS (forward)

-3.22

PEG ratio

n/a

Price to book

3.37

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.94

Employees

141

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Maze Therapeutics, Inc. and compare it with other stocks.